The GlaxoSmithKline psychiatric drug Paxil is the topic of the third and final part of a series of unsolicited guest blog submissions by Jonathan Leo, PhD, and Jeffrey Lacasse, PhD.
Paxil, GlaxoSmithKline, and the University of Pennsylvania
In June of 2012 charges of ghostwriting were made by a University of Pennsylvania Professor over a 2001 paper published in the American Journal of Psychiatry which reported on the use of Paxil in the treatment of manic depressive disorder. The University of Pennsylvania conducted an investigation and concluded that the paper was not ghostwritten. The committee report concluded that although a medical writer helped write the paper, the listed authors satisfied all authorship criteria and the publication presented the research findings accurately. However, statements that the named authors deserved to be on the byline, or that the paper was accurate, have nothing to do with the issue of ghostwriting.
If everyone agrees that a prominent medical writer wrote an early draft of this paper but was not listed on the byline, shouldnt this mean the paper was ghostwritten? One must look closely at Penn Medicines logic to see how they conclude that a paper with an invisible author was not considered ghostwritten. They declare that: While current Perelman School of Medicine policy and journal practice call for acknowledgment of the assistance of a medical writer, the committee concluded that guidelines in place in 2001 did not. But again, whether there were policies in place or not is immaterial in determining if the paper was ghostwritten. In general, policies or laws are put into place to curb existing practices that are seen as harmful. On the date a policy is enacted the practice is now considered forbidden, but that doesnt mean that before the policy was enacted the practice never happened. The existence of a policy banning ghostwriting would play a role in determining whether there was a punishment or not, but it wouldnt play a role in determining if the paper was ghostwritten. It would have been more accurate for Penn Medicine to acknowledge that the paper was ghostwritten, but that because there were no prohibitions against ghostwriting in 2012 that they werent going to pursue the matter. It will be hard for academic medicine to move forward and curb the practice of ghostwriting if they cannot agree on what constitutes a ghostwritten paper.
Even more problematic is that Penn Medicine has a new policy on ghostwriting that simply calls for mentioning medical writers in the acknowledgment section of the paper. Why shouldnt a deserving author be on the byline? Will undergrads be allowed to abide by the same policy and use paid writers to author their first drafts as long as they thank the authors for editorial assistance? (We have discussed the Penn Medicine case extensively in Medical Ghostwriting: A University-Sanctioned Sleight of Hand? in Society.)
Paxil, GlaxoSmithKline, and the American Psychiatric Association
The textbook Recognition and Treatment of Psychiatric Disorders, was published in 1998 by the American Psychiatric Press (APP) in 1998. The named authors are Charles Nemeroff, current chairman of Psychiatry at the University of Miami, and Alan Schatzberg, former Chairman of Psychiatry at Stanford and former President of the American Psychiatric Association. Documents released as part of discovery in a law suit against GlaxoSmithKline have led to allegations that the textbook involved ghost authors employed by the manufacturer of Paxil. A seemingly damning draft of the book by the medical writers is available on the web. In response to these complaints the APPs trade journal, Psychiatric Times, defended the textbooks use of medical writers and declared that they stand behind the authorship line. According to the APP, because Nemeroff and Schatzberg signed-off on the final copy, the article was not ghostwritten. James Scully, Medical Director for the APA, even stated, The book was reviewed for any potential bias (among other things) by eight independent reviewers, and there was no undue influence on the content from industry or any other outside source. But his defense of the book does not get at the pertinent question. It does not matter if the book was reviewed by outside experts. What matters is: Were there individuals who made significant contributions to the book but are not on the byline? All the documents released so far in this case, lead to the conclusion that Sally Laden and Diane Coniglio, who are both paid medical writers, deserve to be on the byline which means that the book should be considered ghostwritten.
To defend the book on the grounds that sympathetic reviewers did not find a problem with the book, is not important in determining if the book was ghostwritten, but it does provides a window into the APAs belief that readers dont really need to concern themselves with the knowing the true authors of one of their publications. As long as a publication is given the APA seal of approval that should be enough. Having eight friends review your paper is a great idea but it has nothing to do with ghostwriting charges. It does not seem appropriate for an academic organization or an academic publisher to defend the idea that readers do not need to know who writes their publications.
Ghostwriting is neither rare nor insignificant. Virtually every single blockbuster medication has been tainted by charges of ghostwriting, and some of these medications have had significant negative effects on public health. Unfortunately, until medical schools and journals make it absolutely clear that the bylines on medical papers should be accurate, readers should realize that the papers they are reading might be written by company employees. There is no reason that companies and university professors shouldnt work together. But when they collaborate on papers just call an author an author.
In the examples we have provided the only reason that one can detect the presence of ghosts is because internal company documents have been made publicly available. For most medical papers this is clearly not the norm, which makes it impossible to know the true prevalence of ghostwritten papers. Some have suggested that it is close to 100% for clinical trials in certain fields. If the academic community cannot agree on the simple premise that a paper with invisible authors on the byline should be labeled as ghostwritten, then efforts to curb the practice will be difficult. The most well documented case of a ghostwritten paper is Study 329. The US Department of Justice (DOJ) recently fined GlaxoSmithKline three billion dollars, in part because of Study 329. In their complaint about Paxil and the role of Study 329 the DOJ did not mince words: The United States argues that, among other things, GSK participated in preparing, publishing and distributing a misleading medical journal article that misreported that a clinical trial of Paxil demonstrated efficacy in the treatment of depression in patients under age 18, when the study failed to demonstrate efficacy. They also note that: GSK published an article that misstated Paxils efficacy and safety for children and adolescents. Yet, both the journal that published it and the university that employed the lead author still stand by the paper.
We welcome any comments on this piece especially regarding whether the examples we provided should be considered ghostwritten or not.
Jonathan Leo examines the biological basis of mental disorders such as ADHD, schizophrenia, and clinical depression. Rethinking ADHD: From Brain to Culture, a co-edited volume with psychiatrist Sami Timimi, was released by Palgrave Macmillan in 2009.
Jeff Lacasse has published research on barriers to evidence-based mental health practice, including articles on critical thinking in mental health, clinical treatment of children, and psychiatric medications.
Together they have published several articles on the serotonin theory of depression and ADHD. Over the past several years their articles on ghostwriting have appeared in PLoS Medicine, The Chronicle of Higher Education, and Society.
Follow the work of HealthNewsReview.org on Facebook, and on Twitter: